WO2007046386A1 - Functional material and functional food comprising useful phospholipid composition - Google Patents

Abstract

Disclosed is a functional material (1) comprising a useful phospholipid composition. The composition has a useful phospholipid composition comprising an ω-3 highly-unsaturated fatty acid-bound phospholipid and a functional substance as active ingredients. The functional substance (3) may be encapsulated in a liposome (2) formed from the useful phospholipid composition. The useful phospholipid is formed into a liposome in water while mixing the functional substance simultaneously to thereby form a useful phospholipid liposome having a physiologically active ingredient of the functional substance encapsulated therein. The useful phospholipid liposome can improve the systemic adsorption efficiency of the functional substance and therefore exert the physiological function of the functional substance in a small quantity at a satisfactory level.

Description

 Specification

 Functional materials and functional foods containing useful phospholipid compositions

 Technical field

 [0001] The present invention relates to a functional material containing a useful phospholipid composition and a functional food to which the functional material is added. More specifically, a functional material containing a useful phospholipid composition and a functional substance as active ingredients, a functional material containing a functional substance in a ribosome formed by the useful phospholipid composition, and the functional material Relates to functional foods. Background art

 [0002] In recent years, various functional foods have attracted attention as health consciousness increases. One of them is a useful phospholipid obtained from seafood (see Patent Document 1, Non-Patent Document 1). It contains a lot of polyunsaturated fatty acid esters such as EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) that are useful for human health.匕 has also been done.

 [0003] There are various components that constitute various functional substances useful for the human body. For example, lipophilic components are poorly soluble in powerful human body fluids such as water and blood, so the absorption efficiency into the human body is low. There are cases where expensive and valuable materials are always wasted. Various formulation technologies for improving the absorption efficiency of these lipophilic components and hydrophilic components have been proposed and have become important elemental technologies in the food and pharmaceutical fields.

 [0004] In recent years, as a material mainly belonging to the category of functional foods, by taking various naturally derived functional food materials orally, it has been widely used in recent years to improve body modulation (metabolic syndrome, etc.) resulting from disorder of lifestyle habits. Some have come to be used. Among these, there are many expensive materials with a small supply amount because of the limited production volume that makes it difficult to obtain raw materials. For example, Agaritas (Non-patent document 2), Coenzyme Q10 (Non-patent document 3), Bulletin, Rutin, Wastaxanthin and the like can be mentioned. It is desirable to improve the bioavailability of these expensive and valuable functional substances, that is, to achieve the same or better effect in a smaller amount.

Patent Document 1: Japanese Patent Application Laid-Open No. 11 123052 Patent Document 2: JP 2002-272493 A

 Non-Patent Document 1: Yoshie Inoue, Food and Development, 31, 1, p. 49

 Non-Patent Document 2: Agaritas Internet <URL: HYPERLINK "http://www.aicplus.com/about http://www.aicplus.com/about agaricus / index, html, August 19, 2005 Search

 Non-Patent Document 3: Japan Coenzyme Q Association Internet URL: HYPERLINK "http: / / www. Coenzymeq-jp.com/ enterprise. Html # qlO〃http: //www.coenzymeq—jp.com/ ente rprise.html # qlO, searched on August 19, 2005

 Non-Patent Document 4: Fragrance Journal, No. 15, p. 68-76, 1965

 Disclosure of the invention

 Problems to be solved by the invention

[0006] However, until now, no functional material that can be used for functional foods and preparations that can more efficiently absorb functional substances useful for the human body has been obtained. .

[0007] In view of the above problems, the present invention includes a useful phospholipid composition in which a useful phospholipid and a functional substance are used as active ingredients, and the physiological function is effectively utilized to improve physiological activity. For the purpose of providing functional materials and functional foods containing them!

 Means for solving the problem

[0008] The present inventors have conducted intensive research and combined useful phospholipids and functional substances in combination, or useful phospholipids containing functional substances in ribosomes of useful phospholipids. It has been found that the functional material containing the composition can enhance its physiological function as compared with the case where the functional substance is administered alone, and the present invention has been completed.

[0009] In order to achieve the above object, the functional material containing the useful phospholipid composition of the present invention comprises a useful phospholipid composition containing omega-3 highly unsaturated fatty acid-binding phospholipid and a functional substance as active ingredients. It is characterized by that.

 According to the above configuration, it is possible to provide a functional material containing a useful phospholipid composition having a very high physiological activity function due to a synergistic effect of a physiological activity function of the phospholipid composition useful for the human body and the functional substance.

[0010] The functional material containing the useful phospholipid composition of the present invention is omega-3 highly unsaturated. It consists of a ribosome comprising a useful phospholipid composition containing a fatty acid-binding phospholipid and a functional substance, wherein the functional substance is encapsulated in the ribosome.

 According to this configuration, functional substances useful for the human body are encapsulated in ribosomes formed from useful phospholipids with excellent emulsifying properties, and increase the bioavailability in the body, thereby increasing the bioactive function. Can be improved.

 [0011] In the above configuration, the omega-3 polyunsaturated fatty acid-binding phospholipid is composed of 10% by weight or more, preferably 20% by weight or more, of DHA (docosahexaenoic acid) and Z Or EPA (eicosapentaenoic acid).

 The omega-3 polyunsaturated fatty acid-binding phospholipid is preferably a useful phospholipid composition in which the content of omega-3 polyunsaturated fatty acid is increased by transesterification. The functional substance is preferably a functional food material or a pharmaceutical material. The functional substance is preferably agaritas or coenzyme Q10.

 The omega-3 polyunsaturated fatty acid-binding phospholipid is preferably derived from aquatic products, and the aquatic organism is preferably any of fish eggs, aquatic animal gonads, squid, scallops, starfish, seaweeds and microorganisms. .

 [0012] According to the above configuration, the useful phospholipid is a naturally-derived omega-3 polyunsaturated fatty acid-binding phospholipid, and contains a food material or a pharmaceutical material as a functional substance, or these It is possible to provide a functional material containing a useful phospholipid composition encapsulating the functional substance. In particular, when the functional substance is agaritas or coenzyme Q10, the effect is significantly higher than that of any single unit of omega-3 highly unsaturated fatty acid-binding phospholipid or agaritas. .

 [0013] The functional food of the present invention preferably contains a functional material containing the useful phospholipid composition. In this case, the functional food may be a solid food or a beverage.

 According to the above configuration, it is possible to provide a functional food that can ingest a force such as a solid food or a beverage with a functional material containing a useful phospholipid composition encapsulating a functional substance. The invention's effect

[0014] According to the present invention, useful phospholipid compositions and functional substances are contained or useful It is possible to provide a functional material that can encapsulate a functional substance in a ribosome having a lipid composition and improve its bioavailability and a food containing the functional material. In particular, when taken as a beverage, the absorption efficiency of functional substances in the body can be improved.

 Brief Description of Drawings

 [0015] FIG. 1 is a diagram schematically showing the structure of another functional material of the present invention.

 FIG. 2 is a view showing the size of cancer cells inoculated in mice when water containing the compositions of Example 1 and Comparative Examples 1 and 2 was freely ingested.

 FIG. 3 is a graph showing the weight% of cancer cells on the 21st day relative to the body weight in Example 1 and Comparative Examples 1 and 2.

 FIG. 4 is a graph showing the weight of cancer cells inoculated in mice when water containing the compositions of Example 2 and Comparative Examples 1 and 2 was freely ingested.

 Explanation of symbols

[0016] 1: Ribosome preparation containing functional substance

 2: Ribosome with useful phospholipid power

 3: Functional substances

 BEST MODE FOR CARRYING OUT THE INVENTION

Hereinafter, embodiments of the present invention will be described in detail with reference to the drawings.

 First, a functional material containing the useful phospholipid composition of the present invention will be described. The functional material containing the useful phospholipid composition of the present invention comprises a useful phospholipid composition and a functional substance as active ingredients. In a useful phospholipid composition containing a useful phospholipid as a main component, the phospholipid is, for example, a glycerin phosphate ester represented by the chemical formula (1), including seafood, egg yolk, soybeans, and the like. It is contained in a lot and is used for extraction.

[Chemical 1] H ₂ C— OOCF ^

 I

R ₂ COO— CH O

 I II

H ₂ C— O— P— O— X

 I

OH where R COO, R COO are fatty acid residues, X is choline (PC), ethanolamine

 1 2

 For example, an alcoholamine group whose force is selected from (PE), inositol (PI), serine (PS), and glycerol (PG). The group X may be a group in which a polyhydric alcohol is ester-bonded.

 Examples of such glycerin phosphates include phosphatidylcholine represented by chemical formula (2) and phosphatidylserine represented by chemical formula (3).

[Chemical 2]

H ₂ C— OOCF ^

 I

R ₂ COO-CH

 I II

H ₂ C— O— P— O— CH ₂ — CH ₂ N + (CH ₃ ) 3

[Chemical 3]

H ₂ C— OOCF ^

R OO-CH O O

 I II II

 H-F C-one O- P- O- CH-one CH- C-〇H

 i i

OH NH ₂ where R COO and R COO are fatty acid residues and are represented by the chemical formula (1)

 1 2

The acid ester X is choline (PC) or serine (PS). [0019] Fatty acid residue strength RCOO DHA (docosahexaenoic acid) group, EPA (eicosapen

1

 The chemical structural formula in the case of (taenoic acid) group is shown in the following formulas (4) and (5). These DHA and EPA are both called omega (ω) -3 highly unsaturated fatty acids because the carbon located third from the end has an unsaturated bond. Phospholipids containing unsaturated fatty acids are omega-3 highly unsaturated fatty acid-bound phospholipids. In the present invention, omega-3 polyunsaturated fatty acid-binding phospholipids are called useful phospholipids, or omega-3 phospholipids are called η-3 phospholipids.

 [Chemical 4]

[0020] Useful phospholipids have a structure having a good balance between a phosphate group as a hydrophilic group and an alkyl group and an alkenyl group as a lipophilic group. It exhibits the property of forming ribosomes, which are emulsified fine particles in human cells, and taking in the lyophilic and lipophilic components therein.

[0021] It should be noted that the chemical substance that forms an ester bond to the phosphate part of the useful phospholipid is a phospholipid phosphatidylserine that is a phospholipid bound to phosphatidylcholine that is a main component of phosphatidylcholine, which is a choline. By imparting a positive charge to the surface, it is possible to repel each other electrically in the liquid and to significantly increase the stability of the ribosome in the dispersion. The coexistence concentration is 5% by weight or more and the stability is remarkable, and 60% by weight or less is preferable. In addition, it is essential that fatty acids that are ester-bonded in useful phospholipids include DHA, which is an omega-3 highly unsaturated fatty acid, and Ζ or Ζ. The effect of the present invention can be obtained if omega-3 highly unsaturated fatty acid is contained even in a small amount. The higher the concentration, the more effective. Specifically, a clear effect is exhibited at 10% by weight or more of the fatty acid ester-bonded in the useful phospholipid, and 20% by weight or more is particularly desirable.

 Here, phosphatidylserine may be produced by extracting phospholipids derived from aquatic products, or by converting phospholipids such as phosphatidylcholine by phosphatidyl group transfer reaction in the presence of L-serine (Patent Literature). 2). Further, it may be extracted by transesterification by an enzymatic method or the like. Furthermore, by adding cholesterol appropriately in the range of 1% by weight to 50% by weight, the strength of the ribosome membrane can be increased and the dispersion stability can be improved.

 [0022] The functional substance 2 can be any functional food material or pharmaceutical material! Such functional food materials include mushroom extract such as Agaritas, Meshimakobu, Hanabiratake, Coenzyme Q10, water-soluble peptide, carotenoids such as carotene, polyphenol, tea catechin, yew leaf extract, various herbs, Flavonoids such as isoflavones, folic acid, vitamins, minerals, amino acids, tocopherol, dalcosamine, hyaluronic acid, chondroitin sulfate, collagen, fucoidan, chitin, chitosan, blueberry, lutein, austaxanthin, etc., DHA, EPA, etc. Omega-3 fatty acids and conjugated fatty acids (CLA). Of these, Agaritas is known to exhibit a marked anticancer effect. Coenzyme Q10 is a substance that is also produced in human cells and is called the “genuine element” of the human body, and many products are sold as supplements for health, beauty and physical fitness.

 [0023] In general, pharmaceuticals have inconvenient side effects unlike foods. For example, pile cancer drugs such as adriamycin, cisbratin, and taxol are widely used for cancer treatment because they exhibit excellent cancer-killing cell effects. However, increasing the amount of use to increase the effect increases the side effects such as hair loss and nausea, which hinders treatment. When the efficacy of these pharmaceuticals is enhanced by the functional material containing the useful phospholipid composition of the present invention, the amount of the pharmaceuticals used can be reduced and the level of side effects can be greatly reduced. As a result, one of the excellent effects of the present invention is that the quality of life of the patient can be remarkably improved.

[0024] According to the functional material containing the useful phospholipid composition of the present invention, the phospholipid useful for the human body. Due to the synergistic effect of the physiologically active function of the composition and the functional substance, a functional food having an extremely high physiologically active function can be provided. In particular, when the functional substance is agaritas, the effect can express a higher bioactive function than either the phospholipid composition or the functional substance alone.

 [0025] Next, as another functional material of the present invention, a functional material containing a useful phospholipid composition in which a functional substance is encapsulated in a liposome having omega-13 binding phospholipid power will be described.

 FIG. 1 schematically shows the structure of a functional material containing another useful phospholipid composition of the present invention. In the figure, the functional material containing the useful phospholipid composition of the present invention contains functional substance 3 composed of active ingredients of functional food material and pharmaceutical material in ribosome 2 composed of useful phospholipid 1. ing. Ribosome 2, which contains a functional substance, forms fine particles by emulsifying and aggregating useful phospholipids in water. The particle size of ribosome 2 varies depending on the liposome formation conditions, and is usually 10 m or less, more preferably 1 μm or less.

 Here, as useful phospholipids and functional substances, the same materials as the above functional materials can be suitably used. Further, useful phospholipids may be modified or derivatives of phospholipids to which omega binds and have a liposomal effect. Such lipids may be glycolipids such as digalatatosyldiacylglycerol (DGDG)! /.

 The functional material 1 containing the useful phospholipid composition of the present invention is also referred to as a ribosome preparation 1 containing the functional substance 3 or a ribosome preparation 1 as appropriate.

[0026] The ribosome is a closed vesicle that forms a bilayer membrane composed of useful phospholipids and has an aqueous phase therein. This is different from emulsification, which is a system in which one of the two liquids, such as water and oil, that do not mix is finely divided and dispersed in the other phase. In normal emulsification, the emulsion is stabilized using a surfactant or the like. Although useful phospholipid itself also has a surfactant action, in the present invention, it is used as a bilayer membrane of ribosome. Known forms of ribosomes are multilamellar ribosomes (0.1 μm to several μm) and single membrane ribosomes (0.01 μm to number / zm). The former includes multi-layer ribosomes (MLV), multilamellar ribosomes (OLV), and multiphase ribosomes, and the latter includes small single-membrane ribosomes (SUVs) and large single ribosomes. There are membrane ribosomes (LUV) and giant single membrane ribosomes (GUV). As long as the required amount of functional substance can be retained in the internal aqueous phase or bilayer membrane phase, any of them may be used, but single membrane ribosome is preferable.

 Here, vortexing method, sonication method, reverse-phase evaporation method, etc. can be used as the preparation method of ribosomes (see Non-Patent Document 4). The mass production method may be a polyhydric alcohol method, a heating method, a spray drying method, a mechanochemical method, or the like.

 [0027] The functional material containing the useful phospholipid composition of the present invention can be produced by encapsulating the functional substance 3 in the ribosome when forming a ribosome having a useful phospholipid power. In this case, the functional substance is added in an amount of 1 to 90% by weight, preferably 20 to 70% by weight, inside the ribosome.

 [0028] According to the functional material containing the useful phospholipid composition of the present invention, as shown in Fig. 1, the ribosome 2 is formed with the useful phospholipid, and the functional substance 3 is encapsulated therein. Thus, it is possible to provide a functional material 1 that also has a ribosome power of a useful phospholipid encapsulating a functional substance that improves various bioavailability. Therefore, when used as a functional material containing the useful phospholipid composition of the present invention, it is possible to exert more physical functions than the administration of the functional substance alone.

 In this case, useful phospholipids are known to have many physiological activities, and are also good surfactants. Therefore, a functional material in which useful phospholipids themselves are ribosomed and a functional material is encapsulated therein can be dispersed without using other special additives such as surfactants. For this reason, ribosome 2 can be efficiently formed by adding a useful phospholipid to water and applying a treatment to form a lipid bilayer membrane of phospholipid.

 [0029] Furthermore, useful phospholipids have physiological activities such as liver function improvement, blood pressure lowering, anti-allergy, memory function improvement such as memory ability, and anti-cancer. Synergistic effects with physiologically active ingredients in lipids can also improve the overall physiological function.

[0030] Here, as a mechanism for improving the physiologically active function, the absorption in the small intestine is increased, the decomposition of the functional substance in the intestine or in the body, the maintenance of blood concentration by sustained release, This is thought to be due to the fact that it has a similar structure to the membrane and promotes interaction with cells. In addition, it is presumed that functional substances can be collected at a high concentration in a specific part of the living body (target part of the disease). In addition, the immune cell activity of Peyer's patches of the intestinal tract and ribosomes made with omega-3 highly unsaturated fatty acid-binding phospholipids are effective in inhibiting the growth of cancer cells. Various factors such as the synergistic effect with other physiological functions of the lipid itself or a combined effect thereof are considered, but details are unknown.

 [0031] Next, a method for producing a functional material containing a useful phospholipid composition in which the useful phospholipid of the present invention itself is ribosomally encapsulated with the functional material will be described.

 A ribosome preparation containing the functional substance can be prepared by emulsifying a mixture of the useful phospholipid composition and the predetermined functional substance in water. This emulsification can be carried out by vigorously stirring water, the useful phospholipid composition and the functional substance, or by spraying them through micropores. In particular, when the functional substance is hydrophilic, the functional substance is easily taken up into the phospholipid bilayer membrane of the ribosome and becomes a uniform emulsion (see Fig. 1). Further, when the functional substance is lipophilic, a part or all of the functional substance is sandwiched between layers of the phospholipid bilayer inside the liposome, and held or encapsulated inside the phospholipid. The particle size of ribosome formed by emulsification is 10 / z m or less. The smaller the particle size, the more stable the ribosome in the aqueous medium, and the stability is improved when 5% by weight or more of serine is contained as a chemical substance that forms an ester bond to the phosphate moiety in the useful phospholipid. Depending on the method of ribosomeization, the particle size distribution can be appropriately adjusted. The particle size and particle size distribution should be designed appropriately according to the application.

 [0032] Useful phospholipids include fish eggs such as salmon roe, demolition power such as bonito and tuna, gonads, squid, starfish, and oils derived from aquatic products such as scallops, starfish, seaweed and microorganisms. Extracted and purified omega-3 polyunsaturated fatty acid binding phospholipids can be used.

 [0033] According to the above production method, the functional material containing the useful phospholipid composition in which the useful phospholipid itself of the present invention is ribosomed and the functional material is encapsulated inside or between the phospholipid bilayer membranes. Can be manufactured efficiently.

Example 1 Hereinafter, the present invention will be described in more detail with reference to examples.

As Example 1, a functional material containing a useful phospholipid composition containing a useful phospholipid composition and a functional substance as active ingredients was produced. Specifically, omega-3 highly unsaturated fatty acid-binding phospholipid derived from squid meal dissolved in hexane is placed in an eggplant-shaped flask so that the phospholipid forms a thin film on its side wall under a nitrogen gas stream. Then, the mixture was allowed to dry and then left under reduced pressure to completely distill off the solvent to obtain a dried product. 0.4 g of this dried product was dispersed in 10 OOcm ³ of pure water. On the other hand, lgaritas (manufactured by Health Science Co., Ltd., AICPLUS) water extract lyophilized powder 1 _g was dissolved in 1000 cm ³ of pure water.

 Next, the functional dispersion of Example 1 was prepared by mixing equal amounts of the above aqueous solution of dried solids and an aqueous solution of agaritas.

 Example 2

 [0035] In Example 2, a squid liposome-derived phospholipid is used as a raw material for ribosome 2, and Agaritas (AICPLUS, manufactured by Health Science Co., Ltd.) is used as functional substance 3, and a ribosome preparation containing a functional substance 1 was prepared.

 Agarix was encapsulated in ribosomes from squid omega-3 highly unsaturated fatty acid-binding phospholipids by the following procedure.

 First, a dried product of omega-3 polyunsaturated fatty acid-binding phospholipid was obtained by the same procedure as in Example 1.

Next, 0.5 g of garlicus extract lyophilized powder was dissolved in 1000 cm ³ of pure water, and 0.2 g of the dried product was further added, and the mixture was stirred with a vortex mixer for 20 minutes to effect ribosome formation.

Next, it was passed through a membrane filter having a pore size of 0.4 m 20 times, sizing and sterilization were performed, and a ribosome preparation 1 containing fragritas of Example 2 was prepared. In ribosomal formulation 1 containing the Agari task of Example 2, the emulsion lcm ³ per DHA (omega one 3) the phospholipid content is 0. 2 mg / cm ^3, Agaritasu content per emulsion lcm ³ The amount was 0.5 mg. Here, when the ribosome is charged and stabilized, phosphatidylserine (PS) and cholesterol may be appropriately added during the preparation of the dried product. Next, a comparative example will be described.

 (Comparative Example 1)

Omega 3 highly unsaturated fatty acid-binding phospholipid derived from squid of Comparative Example 1 was prepared in the same manner as in Example 2 except that no agaritas was added. In the ribosome preparation 1 of Comparative Example 1, the content of omega-3 highly unsaturated fatty acid-bound phospholipid containing DHA as the main component per lcm ^{3 of} the emulsion is 0.2 mg / cm ³ .

 [0037] (Comparative Example 2)

 Agaritas alone was designated as Comparative Example 2.

Next, the effects of the compositions prepared in Examples 1 and 2 and Comparative Examples 1 and 2 will be described.

 Each composition was mixed with water and allowed to freely ingest as a beverage in mice (BALBZc), and the effect on cancer cells (SP2tumors) inoculated into the mice was examined. The beverage was given daily from day 7 onwards after cancer cell inoculation.

Here, the mouse used for the test was a BALBZc male (nuZnu), bred at 5 weeks of age, and started the 6-week age test. Cancer cells SP2 were administered subcutaneously to the right armpit of 7 million mice (sample number n = 7). Mice were bred with a diet made from CLEA Japan (CE2). The concentration of each composition prepared in Examples 1 and 2 and Comparative Examples 1 and 2 to water was 0.4 mg / cm ³ .

 First, a comparison between Example 1 and Comparative Examples 1 and 2 will be described.

FIG. 2 shows the size of cancer cells inoculated in mice when water containing the compositions of Example 1 and Comparative Examples 1 and 2 was freely ingested. In Fig. 2, the horizontal axis represents the number of days after cancer cell inoculation, and the vertical axis represents the size (mm ³ ) of cancer cells. The figure also shows the data of mice that freely ingested water that did not contain any of the above-mentioned compositions for comparison with Example 1 and Comparative Examples 1 and 2 (Fig. 1). See no treatment).

As apparent from FIG. 2, the cancer cells of 21 day, Example 1, Comparative Example 1, Comparative Example 2, the case of no administration, ^{respectively, 2mm 3, 4mm 3, 3.} 5mm 3, 7mm 3 Thus, in the case of Example 1, only about 30% proliferated compared with the case of no administration. From this, in the case of Example 1, the effect of suppressing the proliferation of cancer cells was remarkably recognized.

[0040] FIG. 3 shows the weight of the cancer cells on the 21st day relative to the body weight in Example 1 and Comparative Examples 1 and 2. It is the figure which showed quantity%. In the figure, the vertical axis represents the weight% of cancer cells. As is clear from FIG. 3, the weight percentage of cancer cells is 8% (about 24% without administration), 20%, 17% in Examples Comparative Example 1, Comparative Example 2 and no administration, respectively. In the case of the composition of Example 1, the weight percentage of cancer cells was about 24% without administration, and the effect of suppressing the growth of cancer cells was remarkably observed. .

Next, a comparison between Example 2 and Comparative Examples 1 and 2 will be described.

 FIG. 4 is a graph showing the weight of cancer cells inoculated into mice when water containing the compositions of Example 2 and Comparative Examples 1 and 2 was freely ingested. In the figure, the horizontal axis indicates the number of days after cancer cell inoculation, and the vertical axis indicates the weight (g) of cancer cells. The figure also shows the data of a mouse that freely ingested water without any of the above-mentioned composition for comparison with Example 2 and Comparative Examples 1 and 2 (FIG. 4). No administration).

 On the 19th day, the amount of cancer cells was 20g without administration, ribosome alone (Comparative Example 1) 15g, only agaritas (Comparative Example 2) 3g, and in the Examples, lg (5% without administration), and the suppressive effect As can be seen from FIG. 4, mice that freely ingested water containing ribosome formulation 1 containing fragritas in Example 2 showed a gradual growth of cancer cells on the 19th day. 27 g of eyes were alive.

 [0042] Mice that were given free access to water containing DHA (omega 3) phospholipid ribosome derived from squid in Comparative Example 1 showed growth of cancer cells on day 12 and died on day 19, The weight of the cancer cell at that time was 30 g.

 [0043] Mice that were freely ingested with water containing agaritas of Comparative Example 2 showed gradually growing cancer cells from day 13 and reached 40 g on day 35, but survived.

 [0044] On the other hand, in the case of no administration without administration of any composition, the growth of cancer cells was observed from the 12th day and died on the 19th day, and the weight of the cancer cells at that time was 38g. there were.

[0045] According to the above Example 2 and Comparative Example, the growth of cancer cells was slowed in the order of Comparative Example 2 and Example 2 in comparison with no administration and Comparative Example 1 that died on the 19th day. The cancer cell growth inhibitory effect was observed. Furthermore, in the case of the ribosome preparation 1 encapsulating agaritas of Example 2, the cancer cell growth inhibitory effect is further enhanced than the case of the administration of agaritas alone of Comparative Example 2. Admitted. In addition, it was found that the growth of cancer cells was slower in the case of the thread and adult product that only the DHA (omega-3) -bound phospholipid ribosome derived from squid in Comparative Example 1 was used. I helped.

 Example 3

[0046] In Example 3, a ribosome preparation 1 containing a functional substance was prepared in the same manner as in Example 2, except that Coenzyme Q10 (manufactured by Nisshin Faluma) was used as the functional substance 3. A total of 25 mg of a drink (100 cm ³ ) in which the functional material of Example 3 was dispersed was given to ³ healthy males.

 As a comparative example, 10 healthy tablets were administered orally once with 10 quinone lOmg tablets (Coenzyme Q 10 preparation from Eisai Co., Ltd.). In this case, the dose of Coenzyme Q 10 is lOOmg. Blood was collected from both groups over time, and the Coenzyme Q10 concentration in plasma injections was measured. The time course of the Coenzyme Q10 concentration in plasma was almost the same in the Example 3 group and the Comparative group. In both groups, the maximum plasma concentration (0.55-0.70 μg / cm) was reached 6 hours after administration, and then gradually decreased.

 As described above, the beverage containing the functional material 1 in which Coenzyme Q10 of Example 3 is encapsulated in useful phospholipid is efficiently taken into the body in the amount of 1Z4 of the commercial Coenzyme Q10 preparation (Nyquinone), We were able to increase the plasma concentration of Coenzyme Q10. Example 4

 [0047] The functional material 1 containing the useful phospholipid of Example 4 was prepared in the same manner as in Example 2 except that the scallop-derived phospholipid described later was used.

 [0048] The scallop-derived phospholipid was prepared as follows.

 A useful phospholipid composition of Example 4 was produced using scallop as a starting material. The starting material has a scallop mouth weight of 1000kg, which has been drained for a while but not particularly dry (hereinafter referred to as the wet standard). The breakdown is 23% by weight solids and water strength S770kg. The protein in this solid content is about 13.5% in the case of scallop mouth.

First, the starting materials were continuously added, and the first steaming process and the second solid-liquid separation process were continuously performed. Specifically, 2000 liters of water is added to starting material 1 and steam jar is added. It was heated and boiled at a temperature of 95-100 ° C and a residence time of 20 minutes in a continuous heating tube.

[0049] Subsequently, as a second solid-liquid separation step, it was passed through a continuous centrifuge and subjected to rotation of 2000G to obtain a solid and a liquid phase. This liquid phase was recovered as waste. The weight of the solid material obtained in this process was 470 kg, and the water content was 61.7% by Karl Fischer measurement.

 [0050] As an organic solvent extraction process, 100 kg of the above solids (about 38 kg of dry solids) was extracted from a stainless steel cylindrical extraction device (diameter 0.5 m, height 1.5 m, capacity 200 liters). The extraction operation was performed by circulating 300 liters of 95% ethanol at a circulation rate of 100 liters Z. Finally, the residual liquid phase was extruded with air, and this was added to the organic solvent extract to obtain about 400 liters of the organic solvent extract. The solid residue of the extraction residue obtained at this time was 35 kg.

 [0051] As the fourth step, about 400 liters of the organic solvent extract was added to 50 ° C, 650 mmHg (about, 8.7

X 10 ⁴ Pa) under reduced pressure to remove and recover the organic solvent. The extract obtained here was a brown sticky liquid, and its weight was 15.5 kg.

 [0052] As the fifth step, the extract was passed through a stainless steel cup-top column having a diameter of 50 cm and a height of 1.5 m. The chromatographic column is packed with silica gel. Silica gel (Hishigel, manufactured by Dokai Chemical Co., Ltd.) having a particle size of 250 / z πι to 500 / ζ πι was used. Separation was developed with 95 wt% ethanol. Of the effluent phase, the dark black-brown initial fraction was separated and discarded, and then the effluent phase that became light brown was collected as the target fraction.

 [0053] Next, in the sixth step, ethanol was distilled off from the purified solution under the same conditions as in the fourth step to obtain 7.8 kg of an oil phase as a useful phospholipid composition. This useful phospholipid composition had a black-brown appearance and an oily appearance.

 [0054] In the same manner as in Examples 1 and 2, a drinking water addition test to mice was performed. As a result, the amount of cancer cells on day 19 was 1.2 g, 30 g, 4 g, and 39 g in Example 4, Comparative Example 1, Comparative Example 2, and no administration, respectively. In the case of Example 4, the amount of cancer cells was as small as 3% with no administration, showing a very high cancer cell suppression effect.

[0055] From Examples 1 to 4 and Comparative Examples 1 and 2, it was found that the functional material containing the useful phospholipid composition of the present invention has a high cancer cell suppressing effect. The present invention can be variously modified within the scope of the invention described in the claims without being limited to the above embodiments, and it goes without saying that these are also included in the scope of the present invention. For example, the pH in the production process of the ribosome preparation encapsulating the functional substance, the chromatographic column in the purification process by the chromatographic method, and the like can be designed as appropriate. It ’s not only the origin, but it ’s a natural thing! /.

Claims

The scope of the claims  [1] A functional material containing a useful phospholipid composition, comprising a useful phospholipid composition containing omega-3 highly unsaturated fatty acid-binding phospholipid and a functional substance as active ingredients. [2] Omega-3, a useful phospholipid composition containing highly unsaturated fatty acid-binding phospholipids, and a functional substance.  A functional material containing a useful phospholipid composition, wherein the functional substance is encapsulated in the ribosome. [3] The omega-3 polyunsaturated fatty acid-binding phospholipid is not less than 10% by weight, preferably not less than 20% by weight, of DHA (docosahexaenoic acid) and Z or EPA A functional material comprising the useful phospholipid composition according to claim 1 or 2, wherein the functional material is icosapentaenoic acid. [4] The omega-3 highly unsaturated fatty acid-binding phospholipid is converted to omega- 3. A functional material containing the useful phospholipid composition according to claim 3, which is a useful phospholipid composition having a high content of highly unsaturated fatty acids. [5] The functional material containing the useful phospholipid composition according to claim 1 or 2, wherein the functional substance is a functional food material. [6] The functional material comprising the useful phospholipid composition according to claim 1 or 2, wherein the functional substance is a pharmaceutical material. [7] The functional material containing a useful phospholipid composition according to claim 1 or 2, wherein the functional substance is Agaritas. [8] The functional material containing the useful phospholipid composition according to claim 1 or 2, wherein the functional substance is Coenzyme Q10. [9] The omega-3 polyunsaturated fatty acid-binding phospholipid is derived from an aquatic product, and is any of the aquatic product, fish egg, marine animal gonad, squid, scallop, starfish, seaweed, or microorganism. A functional material comprising the useful phospholipid composition according to claim 1 or 2, [10] A functional food comprising a functional material containing the useful phospholipid composition according to any one of [1] to [9]. [11] The functional food according to claim 10, wherein the functional food is a beverage.